Two Sigma Advisers LP Sells 673,900 Shares of Illumina, Inc. (NASDAQ:ILMN)

Two Sigma Advisers LP reduced its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 78.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 181,800 shares of the life sciences company's stock after selling 673,900 shares during the period. Two Sigma Advisers LP owned approximately 0.11% of Illumina worth $24,294,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Golden State Wealth Management LLC bought a new position in shares of Illumina in the 4th quarter worth $32,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Illumina in the 4th quarter worth $45,000. Assetmark Inc. lifted its holdings in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in shares of Illumina in the 4th quarter worth $48,000. Finally, V Square Quantitative Management LLC lifted its holdings in shares of Illumina by 50.6% in the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock worth $52,000 after purchasing an additional 132 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, CFO Ankur Dhingra acquired 6,100 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average price of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Canaccord Genuity Group lowered their price target on Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Morgan Stanley lowered their price target on Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and lowered their price target for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Stephens reissued an "overweight" rating and issued a $105.00 price target on shares of Illumina in a research report on Tuesday. Finally, Citigroup lowered their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Illumina currently has a consensus rating of "Moderate Buy" and a consensus target price of $128.15.

Illumina Stock Performance

Shares of Illumina stock traded down $0.17 during trading hours on Friday, hitting $80.37. 1,536,714 shares of the company's stock traded hands, compared to its average volume of 2,321,525. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The stock has a market capitalization of $12.72 billion, a price-to-earnings ratio of -10.46, a PEG ratio of 1.60 and a beta of 1.35. The company has a fifty day simple moving average of $78.14 and a 200-day simple moving average of $109.01. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the firm posted $0.98 EPS. The firm's revenue for the quarter was down 1.4% on a year-over-year basis. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.